JUBLPHARMA

- Jubilant Pharmova Limited announced the allotment of 80,000 Unsecured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹800 crores on a private placement basis. - The face value per NCD is ₹1,00,000, issued at par, carrying an interest rate of 8.50% p.a. - The tenure of the instrument is 3 years, with the date of allotment on November 05, 2026, and maturity on November 05, 2028. - The NCDs are proposed to be listed on BSE Limited.

Concall Schedule Concall Date: Monday, November 16, 2026 Concall Time: 08:30 am to 09:30 am (IST)

- Jubilant Pharmova Limited has issued a Postal Ballot Notice to seek shareholders' approval for issuing Non-Convertible Debentures (NCDs) up to ₹2,500 crore on a private placement basis. - The remote e-voting period commences on Thursday, October 22, 2026 (9:00 A.M. IST) and concludes on Friday, November 20, 2026 (5:00 P.M. IST). - Mr. Rupinder Singh Bhatia, Practicing Company Secretary, has been appointed as the Scrutinizer for the voting process. - The results of the Postal Ballot will be announced on or before Tuesday, November 24, 2026.

- India Ratings and Research has assigned a credit rating of IND AA+/Stable to Jubilant Pharmova Limited's proposed non-convertible debentures (NCDs). - The rating is for a proposed NCD issue amounting to ₹1,400 crore (14,000 million). - The rating communication was received by the company on October 21, 2026.

- ICRA Limited assigned a credit rating of [ICRA]AA+ (Stable) to Jubilant Pharmova Limited's proposed Non-Convertible Debentures (NCDs) amounting to ₹1,400.00 crore on October 13, 2026. - The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- Jubilant Pharmova Limited approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. - The company will also seek members' authorization via Postal Ballot for issuing debt securities up to ₹2,500 crore outstanding at any point. - NCDs have a face value of ₹1,00,000 each with a tenure of up to five years and are proposed to be listed on BSE.

- Jubilant Pharmova Limited announced the outcome of its Board Meeting held on October 12, 2026. - Approved the issuance of up to 80,000 Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. - Approved seeking members' authorization via Postal Ballot for issuing non-convertible debt securities up to an aggregate amount of ₹2,500 crore outstanding at any point.

Jubilant Pharmova's Radiopharma business announced an investment of CAD 94.5 million to modernize its Kirkland, Québec facility and double the production capacity of RUBY-FILL®. - The Government of Canada will provide financial support of CAD 23.8 million for the project through the Strategic Response Fund.

- The company has issued a specimen letter sent to physical security holders whose final dividend for FY 2025-26 has been withheld. - The withholding is due to the non-submission of mandatory KYC documents and bank details as per SEBI regulations. - Shareholders are requested to submit forms like ISR-1, ISR-2, and nomination details to the RTA to claim their dividend electronically.

- USFDA classified Jubilant HollisterStier LLC's CMO facility (Spokane, WA) as 'Voluntary Action Indicated (VAI)' following an inspection from June 8-17, 2026.

- Jubilant Pharmova received a Show Cause Notice on August 31, 2026, from the Assistant Commissioner of Commercial taxes, Mysore. - The notice demands GST, interest, and penalty totaling ₹87.31 Cr for FY 2022-23. - The Company believes the notice is incorrect, will file a detailed reply, and expects no financial or operational impact.